VP1 pseudocapsids, but not a glutathione‐S‐transferase VP1 fusion protein, prevent polyomavirus infection in a T‐cell immune deficient experimental mouse model

The ability to vaccinate against polyomavirus infection in a T-cell deficient as well as a normal immune context was studied using polyomavirus major capsid protein (VP1) pseudocapsids (VP1-ps) or a glutathione-S-transferase-VP1 (GST-VP1) fusion protein. VP1-ps (1 or 10 μg) were administered subcutaneously, alone or together with Freund's complete and incomplete adjuvant, to CD4−/−8−/− T-cell deficient or normal C57Bl/6 mice on four occasions. Alternatively, CD4−/−8−/− and normal mice were inoculated with either GST-VP1 or Py-VP1-ps (5 μg). Following immunisation, antibody titres were tested by ELISA to VP1-ps or GST-VP1 or by haemagglutination inhibition (HAI). Mice were then infected with polyomavirus. Three weeks post-infection, the mice were killed and examined for the presence of polyomavirus DNA by PCR. Viral DNA was not detected in CD4−/−8−/− mice immunised with either VP1-ps alone or in combination with Freund's complete and incomplete adjuvant, or in any of the normal mice immunised with VP1-ps or GST-VP1. However, viral DNA was detected in 2/5 of the CD4−/−8−/− mice immunised with GST-VP1 and in non-immunised controls. Greater antibody titres were observed to VP1-ps than to GST-VP1 in CD4−/−8−/− mice after VP1-ps compared to GST-VP1 immunisation and antibody responses were better in normal than in immune-deficient mice. Only immunisation with VP1-ps resulted in haemagglutination inhibition. Complete protection against polyomavirus infection in the T-cell deficient context was obtained with VP1-ps, but not with GST-VP1, immunisation using the present vaccination protocol. J. Med. Virol. 70: 293–300, 2003. © 2003 Wiley-Liss, Inc.